Decoy Therapeutics to Present at Two Peptide Therapeutics Conferences in Boston

Rhea-AI Summary

Decoy Therapeutics (Nasdaq: DCOY) will present at two Boston peptide therapeutics conferences the week of April 27, 2026. Executives and advisors will discuss computational peptide design, peptide conjugate antivirals, and share new preclinical D-MAV data. The company highlighted a Quantori partnership and its IMP3ACT platform supporting pan-coronavirus and tripledemic programs.

News Market Reaction – DCOY

+1.57%

1 alert

+1.57% News Effect

+$49K Valuation Impact

$3.19M Market Cap

0.3x Rel. Volume

On the day this news was published, DCOY gained 1.57%, reflecting a mild positive market reaction. This price movement added approximately $49K to the company's valuation, bringing the market cap to $3.19M at that time.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement highlights Decoy’s growing profile in peptide therapeutics, with leadership presen...

Analysis

This announcement highlights Decoy’s growing profile in peptide therapeutics, with leadership presenting across two Boston conferences and sharing new preclinical D-MAV data. It reinforces the role of the IMP3ACT platform and AI-enabled peptide design in targeting shared viral mechanisms, including pan-coronavirus and broad antiviral programs. Set against recent milestones such as Nasdaq compliance, an AI partnership, and a 1-for-12 reverse split, investors may watch for concrete clinical start dates and additional funding or collaboration updates as future markers of progress.

Key Figures

Roundtable duration: 60 minutes Conference date: April 30, 2026 Summit edition: 3rd Annual +1 more

4 metrics

Roundtable duration 60 minutes HubXchange roundtable on computational peptide design

Conference date April 30, 2026 Oligonucleotide & Peptides HubXchange presentation

Summit edition 3rd Annual Peptide-Based Therapeutics Summit

Conference week Week of April 27, 2026 Boston peptide therapeutics conferences

Historical Context

5 past events · Latest: Apr 09 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Apr 09	Pipeline progression	Positive	+6.6%	Outlined accelerated execution and path to Phase 1 targeted for 2027.
Apr 06	Investor event	Neutral	+1.6%	Announced virtual investor ‘Closing Bell’ event and 2026 business outlook.
Apr 02	Listing compliance	Positive	-8.2%	Regained compliance with Nasdaq minimum bid price requirement and monitor period.
Mar 11	AI partnership	Positive	-4.8%	Entered Quantori partnership for Google Cloud-native AI-driven peptide design platform.
Mar 05	Reverse stock split	Negative	-11.3%	Announced 1-for-12 reverse split to support Nasdaq bid price compliance.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent positive corporate and partnership updates have sometimes seen negative price reactions, while structural actions like the reverse split and compliance news drew mixed responses.

Recent Company History

Over the last two months, Decoy Therapeutics has undergone notable transition events and pipeline positioning. A 1-for-12 reverse split on Mar 05 was followed by news of a strategic AI partnership on Mar 11 and regaining Nasdaq minimum bid compliance on Apr 02. Subsequent communications on a targeted 2027 Phase 1 timeline and an investor event in early April framed a path toward clinical development. Today’s conference-focused announcement continues that visibility push around its AI-enabled IMP3ACT platform and D-MAV pipeline.

Key Terms

computational peptide design, generative design, peptide conjugate, de novo design, +4 more

8 terms

computational peptide design technical

"roundtable on Computational Peptide Design CSO Dr. Barbara Hibner"

Computational peptide design uses computer models and algorithms to create and test short chains of amino acids (peptides) on screen, predicting which sequences will bind targets, be stable, and behave safely before any lab work. For investors this matters because it can speed discovery, reduce lab costs and failure risk, and help companies produce more promising drug or diagnostic candidates faster—similar to prototyping many versions digitally before building a single physical product.

generative design technical

"The session will examine how generative design approaches have the"

Generative design is a computer-driven process that takes goals, limits and available materials and produces many possible product shapes and layouts, similar to telling a smart assistant the ingredients you have and getting dozens of recipe options. For investors, it matters because it can cut engineering time, lower manufacturing costs, create lighter or stronger products, and enable faster innovation — all of which can improve margins, shorten time to market and change competitive dynamics.

peptide conjugate medical

"its proprietary peptide conjugate platform, IMP3ACT™, today announced"

Peptide conjugate is a molecule created by attaching a short chain of amino acids (a peptide) to another drug, diagnostic, or chemical to change its behavior—like adding a GPS tag or slow-release coating to a package so it reaches the right place and acts for the right time. For investors, these modifications can improve effectiveness, reduce side effects, enable targeted delivery, and affect manufacturing complexity, regulatory risk, patent protection and therefore a therapy’s commercial potential.

de novo design technical

"natural ligand reengineering to de novo design." The session will"

De novo design is the creation of entirely new biological molecules or drugs from first principles using computer modeling and lab work, rather than tweaking existing natural compounds. Like designing a brand‑new tool instead of upgrading an old one, it can produce unique products with strong patent protection and big commercial upside for investors, but it also brings higher technical, development and regulatory risk because there is no established blueprint.

ligand reengineering medical

"Key challenges in computational design of peptide therapeutics: From natural ligand reengineering"

Ligand reengineering is the process of modifying small molecules or biologic pieces that bind to a target protein so they work better, are safer, or are easier to make. Think of it as reshaping a key so it fits a lock more precisely: improved fit can make a drug more effective, reduce side effects, or lower development cost and risk, which directly affects a drug candidate’s commercial and regulatory value to investors.

machine learning technical

""The Infinite Loop: Machine Learning for Discovery, Delivery & Rapid"

Machine learning is a set of computer programs that learn patterns from large amounts of data and improve their predictions or decisions over time, like a recipe that gets better each time it’s adjusted based on taste tests. For investors it matters because these systems can speed up analysis, spot trends or risks humans might miss, automate routine work, and potentially create competitive advantages or cost savings that affect a company’s performance.

View in glossary

pan-coronavirus medical

"led by a preclinical pan-coronavirus fusion inhibitor and a discovery-stage"

Pan-coronavirus describes medicines, vaccines or diagnostic tools designed to work against a broad range of coronaviruses and their variants by targeting features those viruses share. For investors, a pan-coronavirus product is like a universal charger: one solution can serve many future outbreaks and strains, which can expand the potential market, reduce the risk that a single new variant will make the product obsolete, and therefore affect a developer’s long-term revenue and valuation.

fusion inhibitor medical

"led by a preclinical pan-coronavirus fusion inhibitor and a discovery-stage"

A fusion inhibitor is a type of antiviral drug that stops a virus from merging with a human cell’s outer layer, preventing the virus from entering and infecting the cell. For investors, these drugs matter because successful fusion inhibitors can change a company’s clinical prospects and potential revenue streams—think of them as a lock that keeps an intruder out; if the lock works and is approved, it can create strong market value and competitive advantage.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

CBO Peter Marschel to Lead HubXchange Roundtable on Computational Peptide Design

CSO Dr. Barbara Hibner and CTO Dr. Michael Lipp to Co-Present at Peptide-Based Therapeutics Summit; Advisor Dr. Bradley Pentelute to Deliver Opening Remarks

CAMBRIDGE, Mass., April 27, 2026 /PRNewswire/ -- Decoy Therapeutics Inc. (Nasdaq: DCOY), a preclinical-stage biotechnology company pioneering Designable Multi-Antivirals (D-MAVs ^™), a new category of antivirals engineered to target shared viral mechanisms using its proprietary peptide conjugate platform, IMP³ACT^™, today announced that members of its executive leadership will present across two leading peptide therapeutics conferences in Boston the week of April 27, 2026.

At the Oligonucleotide & Peptides HubXchange on April 30, Chief Business Officer Peter Marschel will lead a 60-minute roundtable discussion titled "Key challenges in computational design of peptide therapeutics: From natural ligand reengineering to de novo design." The session will examine how generative design approaches have the potential to move peptide discovery beyond the traditional evolutionary sampling that shaped therapeutics such as GLP-1 agonists, toward de novo design of peptide drugs against novel targets.

The company recently announced a strategic partnership with Quantori to deploy a Google Cloud-native, AI-driven peptide design and molecular simulation platform, shortening the cycle from peptide design to D-MAV candidates. The collaboration demonstrates how computational work can accelerate the shift from ligand reengineering to de novo design, which Marschel will discuss at HubXchange.

"The most interesting work in peptide therapeutics right now is how quickly we can potentially move, from optimizing naturally occurring ligands to designing ligands. At Decoy, we're especially interested in taking what mother nature gave us in powerful, cross-reactive natural ligands and combining them with modern computational techniques to design drug candidates with activity profiles that haven't been accessible through traditional approaches. We're excited to share what we're seeing and how D-MAVs fit into this throughout the week," said Peter Marschel, Co-Founder and Chief Business Officer of Decoy Therapeutics.

On April 28, at the 3rd Annual Peptide-Based Therapeutics Summit, Chief Scientific Officer Dr. Barbara Hibner and Chief Technology Officer Dr. Michael Lipp will co-present the Spotlight Case Study "Design & Development of Peptide Conjugate Antiviral Therapeutics" during the Peptide Drug Conjugates pre-conference workshop. Their session will show how peptide conjugates enable design-led development of therapeutics built around medical need, moving past the constraints of conventional one-virus, one-drug approaches. The presentation will include new preclinical data from Decoy's D-MAV programs.

"We've spent decades treating viruses one at a time, but peptide conjugates give us something different: a way to design around what viruses share, not just react to what each one does," said Dr. Barbara Hibner, Co-Founder and Chief Scientific Officer of Decoy Therapeutics. "There are hundreds of viruses affecting people around the world and only a handful of targeted treatments. This is a chance to change how we build them, driven by medical need, not by the limits of traditional drug development."

Also at the Peptide-Based Therapeutics Summit, Decoy Technology Advisor Dr. Bradley Pentelute, Professor of Chemistry at the Massachusetts Institute of Technology, will deliver the opening presentation of Day 1 on April 29, "The Infinite Loop: Machine Learning for Discovery, Delivery & Rapid Manufacturing of Potential Medicines."

The presentations come as Decoy advances its D-MAV pipeline, led by a preclinical pan-coronavirus fusion inhibitor and a discovery-stage broad antiviral targeting the "tripledemic" of influenza, COVID-19, and RSV. Both programs are built on the IMP³ACT platform, which integrates AI-enabled peptide design with rapid synthesis and manufacturing to support iteration across viral families.

About Decoy Therapeutics, Inc.
Decoy Therapeutics is a preclinical-stage biotechnology company pioneering Designable Multi-Antivirals (D-MAVs), a new category of antivirals engineered to target shared viral mechanisms. D-MAVs are built on Decoy's proprietary peptide conjugate platform, IMP³ACT, which integrates AI-enabled design with rapid synthesis and manufacturing. Decoy's lead programs focus on respiratory viruses. The company has attracted financing from institutional investors and significant non-dilutive capital from the Massachusetts Life Sciences Seed Fund, the Google AI startup program, and the NVIDIA Inception program, among other sources. The company has also received QuickFire Challenge award funding provided by the Biomedical Advanced Research and Development Authority (BARDA) through BLUE KNIGHT^™, a collaboration between Johnson & Johnson Innovation and BARDA within the Administration for Strategic Preparedness and Response.

Forward-Looking Statements
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 regarding Decoy, including expected achievement of milestones for its lead asset and future prospects of Decoy. These statements may discuss goals, intentions and expectations as to future plans, trends, events, results of operations or financial condition, or otherwise, based on current beliefs of the management of Decoy, as well as assumptions made by, and information currently available to, management. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as "may," "will," "can," "should," "would," "expect," "anticipate," "plan," "likely," "believe," "estimate," "project," "intend," and other similar expressions. Statements that are not historical facts are forward-looking statements. Forward-looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties and are not guarantees of future performance. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors, including, without limitation: the risk that the Company will not obtain sufficient financing to execute on their business plans and risks related to Decoy's products and development plans, including unanticipated issues with any IND application process and the potential of the IMP³ACT platform. Readers are urged to carefully review and consider the various disclosures made by the Company in its reports filed with the SEC, including its Annual Report on Form 10-K for the fiscal year ended December 31, 2025, as revised or supplemented by its Quarterly Reports on Form 10-Q and other documents filed with the SEC. If one or more of these risks or uncertainties materialize, or if the underlying assumptions prove incorrect, Decoy's actual results may vary materially from those expected or projected.

View original content to download multimedia:https://www.prnewswire.com/news-releases/decoy-therapeutics-to-present-at-two-peptide-therapeutics-conferences-in-boston-302753387.html

SOURCE Decoy Therapeutics, Inc

FAQ

When will Decoy Therapeutics (DCOY) present at the Boston peptide conferences in April 2026?

Decoy will present during the week of April 27, 2026, with sessions April 28–30. According to the company, speakers include CBO Peter Marschel, CSO Barbara Hibner, CTO Michael Lipp, and advisor Bradley Pentelute.

What topics will Decoy Therapeutics (DCOY) cover at the HubXchange and Peptide-Based Therapeutics Summit?

Decoy will address computational peptide design, peptide conjugate antivirals, and AI-enabled discovery. According to the company, sessions cover generative design, design-led antiviral development, and machine learning for rapid drug discovery and manufacturing.

Which Decoy Therapeutics (DCOY) leaders are presenting preclinical D-MAV data and when?

CSO Dr. Barbara Hibner and CTO Dr. Michael Lipp will co-present a Spotlight Case Study on April 28. According to the company, their session will include new preclinical data from D-MAV programs.

How does Decoy Therapeutics (DCOY) say it is using AI and partnerships for peptide design?

Decoy says it partnered with Quantori to deploy a Google Cloud-native, AI-driven peptide design and simulation platform. According to the company, this collaboration aims to shorten design-to-candidate cycles via the IMP3ACT platform.

What antiviral programs does Decoy Therapeutics (DCOY) describe as advancing on IMP3ACT?

Decoy lists a preclinical pan-coronavirus fusion inhibitor and a discovery-stage broad antiviral targeting influenza, COVID-19, and RSV. According to the company, both programs are built on the IMP3ACT peptide conjugate platform.